<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890433</url>
  </required_header>
  <id_info>
    <org_study_id>2015-06Obs-CHRMT</org_study_id>
    <nct_id>NCT02890433</nct_id>
  </id_info>
  <brief_title>Standard Precautions Versus Contact Additional Precautions Against Multi-drug Resistant Bacteria in Intensive Care Unit (PSBMR)</brief_title>
  <acronym>PSBMR</acronym>
  <official_title>Are Standard Precautions as Efficient as Contact Additional Precautions Against the Transmission of Multi-drug Resistant Bacteria in Intensive Care Unit ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional Metz-Thionville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional Metz-Thionville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The national recommendations promote the applying of the Contact Additional Precautions (CAP)
      with the Standard Precautions (SP) to limit the transmission of multi-drug resistant (MDR)
      bacteria. However, that could entail more costs and a reduction of quality of the patient
      care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The national recommendations promote the applying of the Contact Additional Precautions (CAP)
      with the Standard Precautions (SP) to limit the transmission of multi-drug resistant (MDR)
      bacteria. However, that could entail more costs and a reduction of quality of the patient
      care.

      This study seeks showing it in way of a non-interventional research in a resuscitation unit.
      Two periods are compared for noticing the rates of MDR bacteria contaminations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Meticillin Resistant Staphylococcus Aureus (MRSA) and Enterobacteriaceae producing Extended Spectrum Beta-Lactamase (EESBL) per 1000 hospitalization days</measure>
    <time_frame>1000 days</time_frame>
  </primary_outcome>
  <enrollment type="Actual">3124</enrollment>
  <condition>Multi-drug Resistant Bacteria</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients hospitalized in the resuscitation unit of the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalization in resuscitation unit

        Exclusion Criteria:

          -  opposition for gathering data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jocelyne SELLIES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Metz-Thionville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR Metz-Thionville</name>
      <address>
        <city>Metz Cedex 03</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

